Evidence map›Paper›PMID 40504836›Full record

ArticlePloS one2025

Synthesis of novel N-substituted β-amino acid derivatives bearing 2-hydroxyphenyl moieties as promising antimicrobial candidates targeting multidrug-resistant Gram-positive pathogens.

Povilas Kavaliauskas, Birutė Grybaitė, Birute Sapijanskaite-Banevič, Rūta Petraitienė, Ramunė Grigalevičiūtė, Andrew Garcia, Ethan Naing, Vytautas Mickevičius, Sergey Belyakov, Vidmantas Petraitis

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Povilas KavaliauskasDepartment of Organic Chemistry, Kaunas University of Technology, Kaunas, Lithuania.ORCID 0000-0003-0237-9088
Birutė GrybaitėDepartment of Organic Chemistry, Kaunas University of Technology, Kaunas, Lithuania.
Birute Sapijanskaite-BanevičDepartment of Organic Chemistry, Kaunas University of Technology, Kaunas, Lithuania.
Rūta PetraitienėDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, United States of America.
Ramunė GrigalevičiūtėBiological Research Center, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Andrew GarciaDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, United States of America.
Ethan NaingDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, United States of America.
Vytautas MickevičiusDepartment of Organic Chemistry, Kaunas University of Technology, Kaunas, Lithuania.
Sergey BelyakovLatvian Institute of Organic Synthesis, Laboratory of Physical Organic Chemistry, Riga, Latvia.
Vidmantas PetraitisDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of antimicrobial resistance among ESKAPE group pathogens presents a significant challenge in the healthcare sector, contributing to higher morbidity and mortality rates globally. Thus, it is essential to develop novel antimicrobial agents effective against drug-resistant pathogens. In this study, we report the synthesis and in vitro antimicrobial activity characterization of novel N-substituted β-amino acid derivatives bearing 2-hydroxyphenyl core against multidrug-resistant bacterial pathogens. The synthesized compounds (2-26) exhibited promising antimicrobial activity specifically against Gram-positive bacteria, with minimum inhibitory concentrations (MIC) ranging from 4 to 128 µg/mL. Compounds 9 (R = 4-nitrophenyl), 17 (R = 5-nitro-2-thienyl), 18 (R = 5-nitro-2-furyl), thiosemicarbazide 16, and 26 exhibited the most promising activity against Staphylococcus aureus MRSA USA300 lineage strain TCH-1516, with MIC values between 4 and 16 µg/mL. Compound 26 demonstrated strong antimicrobial activity against both S. aureus TCH-1516 and E. faecalis AR-0781, with the activity comparable to control antibiotics. Furthermore, compound 26 exhibited antifungal activity drug-resistant against Candida albicans AR-0761 (MIC 16 µg/mL). These findings indicate that N-substituted β-amino acid derivatives with a 2-hydroxyphenyl core warrant further investigation as a potential scaffold for the further development of antimicrobial agents based on compound 26 targeting Gram-positive pathogens and drug-resistant C. albicans AR-0761.

Indexed as

Amino AcidsAnti-Bacterial AgentsAnti-Infective AgentsDrug Resistance, Multiple, BacterialGram-Positive BacteriaCandida albicansHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsAmino AcidsAnti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID40504836
PMCPMC12161524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.